• Contact us: 01476 247 007
    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine preventionGood news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine preventionGood news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine preventionGood news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    What happens after Brexit for Pharmacovigilance and Regulatory?
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020
    Advice for Management of Clinical trials in relation to Coronavirus
    Advice for Management of Clinical trials in relation to Coronavirus
    13th March 2020

    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention

    17th February 2020
    NICE agrees to look again at Novartis’ Aimovig for migraine prevention

    The UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS funding of Novartis’ Aimovig for migraine prevention after an appeal.

    NICE agrees to look again at Novartis’ Aimovig for migraine preventionThe appeals panel has concluded the rejection of Aimovig (erenumab) last September was flawed because NICE’s technology appraisal committee “failed to consider all of the evidence about the cost-effectiveness” of the drug.

    British Association for the Study of Headache chairman, Dr Mark Weatherall said: “Having found that erenumab is cost-effective versus the best supportive care in patients with chronic migraine, it cannot be right or fair to deny it to those worst affected patients who have not responded to Botox and other preventative medications.”

    Pure Drug Safety is one of the leading players in the pharmacovigilance outsourcing market and the owner, Carol Kingstone commented: “At PDS we are welcoming NICE’s decision to review their previous decision on funding Aimovig to make it available for chronic migraine sufferers, if their clinician thinks it could improve their quality of life. We await the results of the review with interest.”

    Aimovig became the first drug in a new class of antibody-based CGRP inhibitors to be approved in Europe when it got a green light from the European Medicines Agency (EMA) last year. It costs around £5,000 per year, although Novartis has offered the NHS a confidential discount.

    For more information, visit the original article by clicking here.

    Share

    Related posts

    21st July 2021

    The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?


    Read more
    GCP Inspections: Expectations and the dos and don’ts for hosting
    19th March 2020

    GCP Inspections: Expectations and the dos and don’ts for hosting


    Read more
    Advice for Management of Clinical trials in relation to Coronavirus
    13th March 2020

    Advice for Management of Clinical trials in relation to Coronavirus


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA